ReviewCellular and molecular life sciences : CMLS2026
Proteasomal control of transcription factors: mechanisms, regulation and dysregulation.
Review in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Revisiting the clastosome: a stress-induced nuclear proteolytic compartment of mammalian cells.Frontiers in neuroanatomy · 2026Review
- Breaking the proteasome balance: α-synuclein and the ubiquitin-proteasome system.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulation of transcription is of key importance for essentially all aspects of biology. Accordingly, transcription factors (TFs) are often subject to rapid degradation, which in turn allows for strict regulation of gene expression and prevents uncontrolled activation or repression of target genes. This rapid turnover is a result of highly effective ubiquitin-dependent and -independent systems specifically selecting individual TFs for proteasomal degradation. The importance of life-time regulation of TFs is underscored by a broad range of diseases connected with dysfunctional TF degradation. Here, we summarize transcriptional regulation through controlled TF degradation. We focus on human TFs and highlight recent advances in our understanding of how TFs are selected for degradation through various proteasomal degradation pathways, and the implications of aberrant TF degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.